Sagimet Biosciences Inc. Stock-Based Compensation
Sagimet Biosciences Inc. (SGMT) reported Stock-Based Compensation of $5.53 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-11
- Sagimet Biosciences Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.69M, a 130.98% increase year-over-year.
- Sagimet Biosciences Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.84M, a 24.93% increase year-over-year.
- Sagimet Biosciences Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.69M, a 10.23% increase year-over-year.
- Sagimet Biosciences Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.69M, a 9.18% increase year-over-year.
- Sagimet Biosciences Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $6.45M, a 21.96% increase from fiscal 2024.
- Sagimet Biosciences Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $5.29M, a 5.97% increase from fiscal 2023.
- Sagimet Biosciences Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $4.99M, a 165.43% increase from fiscal 2022.
- Sagimet Biosciences Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $1.88M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $5.53M 10-Q · filed 2026-08-11 | $7.22M derived: sum of 3 quarters · filed 2026-08-11 | $8.91M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.84M 10-Q · filed 2026-05-12 | $3.53M derived: sum of 2 quarters · filed 2026-05-12 | $5.22M derived: sum of 3 quarters · filed 2026-05-12 | $6.82M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $3.38M derived: sum of 2 quarters · filed 2026-03-11 | $4.98M derived: sum of 3 quarters · filed 2026-08-11 | $6.45M 10-K · filed 2026-03-11 |
| 2025-09-30 | $1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.29M derived: sum of 2 quarters · filed 2026-08-11 | $4.76M 10-Q · filed 2025-11-13 | $6.29M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $3.07M 10-Q · filed 2026-08-11 | $4.60M derived: sum of 3 quarters · filed 2026-08-11 | $6.15M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.47M 10-Q · filed 2026-05-12 | $3.01M derived: sum of 2 quarters · filed 2026-05-12 | $4.55M derived: sum of 3 quarters · filed 2026-05-12 | $6.00M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $3.08M derived: sum of 2 quarters · filed 2026-03-11 | $4.53M derived: sum of 3 quarters · filed 2026-03-11 | $5.29M 10-K · filed 2026-03-11 |
| 2024-09-30 | $1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.00M derived: sum of 2 quarters · filed 2025-11-13 | $3.75M 10-Q · filed 2025-11-13 | $5.07M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $2.21M 10-Q · filed 2025-08-13 | $3.52M derived: sum of 3 quarters · filed 2025-08-13 | $5.37M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $759.00K 10-Q · filed 2025-05-08 | $2.07M derived: sum of 2 quarters · filed 2025-05-08 | $3.92M derived: sum of 3 quarters · filed 2025-05-08 | $4.98M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $3.17M derived: sum of 2 quarters · filed 2025-03-12 | $4.22M derived: sum of 3 quarters · filed 2025-03-12 | $4.99M 10-K · filed 2025-03-12 |
| 2023-09-30 | $1.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $2.91M derived: sum of 2 quarters · filed 2024-11-14 | $3.68M 10-Q · filed 2024-11-14 | $4.40M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.82M 10-Q · filed 2024-08-14 | $2.54M derived: sum of 3 quarters · filed 2024-08-14 | $2.93M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $767.00K 10-Q · filed 2024-05-15 | $1.49M derived: sum of 2 quarters · filed 2024-05-15 | $1.88M derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | $721.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $1.11M derived: sum of 2 quarters · filed 2024-03-25 | $1.88M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $389.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.16M 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $770.00K 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |